Literature DB >> 29140875

Bone Mineral Density Declines Twice as Quickly Among HIV-Infected Women Compared With Men.

Kristine M Erlandson1, Jordan E Lake2, Myung Sim3, Julian Falutz4, Carla M Prado5, Ana Rita Domingues da Silva6, Todd T Brown7, Giovanni Guaraldi8.   

Abstract

BACKGROUND: Initial declines in bone mineral density (BMD) after antiretroviral therapy initiation in HIV are well described, but data on long-term changes and risk factors for decline, particularly among women, are limited.
METHODS: HIV-infected men and women in the Modena Metabolic Clinic underwent dual-energy X-ray absorptiometry (DXA) scans every 6-12 months for up to 10 years (median 4.6 years). Mixed effect regression models in combined and sex-stratified models determined annual rates of decline and clinical factors associated with BMD. Models included demographics, HIV-specific factors, and bone-specific factors; a final model added a sex × time interaction term.
RESULTS: A total of 839 women and 1759 men contributed ≥2 DXA scans. The majority (82%) were 50 years and younger; 76% had HIV-1 RNA <50 copies per milliliter at baseline; 15% of women were postmenopausal and 7% of men had hypogonadism; and 30% and 27%, respectively, had hepatitis C virus (HCV) coinfection. The adjusted slopes in BMD among women and men were significantly different at both the femoral neck (women -0.00897 versus men -0.00422 g/cm per year; P < 0.001) and L-spine (women -0.0127 versus men -0.00763 g/cm per year; P < 0.001). Modifiable risks associated with BMD decline included antiretroviral therapy exposure (greater decline with tenofovir disoproxil fumarate and less decline with integrase strand transfer inhibitor therapy), HCV, physical activity, and vitamin D insufficiency.
CONCLUSIONS: Among HIV-infected individuals, bone density at the femoral neck, a significant predictor of fracture risk, declined twice as quickly among women compared with men. Female sex was independently associated with both lower femoral neck and lumbar BMD over time in adjusted models.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29140875      PMCID: PMC5807215          DOI: 10.1097/QAI.0000000000001591

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  35 in total

1.  Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density.

Authors:  Kristine M Erlandson; Douglas Kitch; Camlin Tierney; Paul E Sax; Eric S Daar; Pablo Tebas; Kathleen Melbourne; Belinda Ha; Nasreen C Jahed; Grace A McComsey
Journal:  AIDS       Date:  2013-08-24       Impact factor: 4.177

Review 2.  Bone Density and Fractures in HIV-infected Postmenopausal Women: A Systematic Review.

Authors:  Yamnia I Cortés; Michael T Yin; Nancy K Reame
Journal:  J Assoc Nurses AIDS Care       Date:  2015-04-03       Impact factor: 1.354

Review 3.  HIV and Bone Complications: Understudied Populations and New Management Strategies.

Authors:  Michael T Yin; Todd T Brown
Journal:  Curr HIV/AIDS Rep       Date:  2016-12       Impact factor: 5.071

4.  Predictors of longitudinal change in bone mineral density in a cohort of HIV-positive and negative patients.

Authors:  Willard Tinago; Aoife G Cotter; Caroline A Sabin; Alan Macken; Eoin Kavanagh; Jennifer J Brady; Geraldine McCarthy; Juliet Compston; Patrick W G Mallon
Journal:  AIDS       Date:  2017-03-13       Impact factor: 4.177

5.  Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy.

Authors:  Adrian Curran; Esteban Martinez; Maria Saumoy; Luis del Rio; Manuel Crespo; Maria Larrousse; Daniel Podzamczer; Joaquin Burgos; Montse Lonca; Pere Domingo; Jose Maria Gatell; Esteban Ribera
Journal:  AIDS       Date:  2012-02-20       Impact factor: 4.177

6.  Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.

Authors:  Todd T Brown; Carlee Moser; Judith S Currier; Heather J Ribaudo; Jennifer Rothenberg; Theodoros Kelesidis; Otto Yang; Michael P Dubé; Robert L Murphy; James H Stein; Grace A McComsey
Journal:  J Infect Dis       Date:  2015-05-05       Impact factor: 5.226

7.  Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration.

Authors:  Colette J Smith; Lene Ryom; Rainer Weber; Philippe Morlat; Christian Pradier; Peter Reiss; Justyna D Kowalska; Stephane de Wit; Matthew Law; Wafaa el Sadr; Ole Kirk; Nina Friis-Moller; Antonella d'Arminio Monforte; Andrew N Phillips; Caroline A Sabin; Jens D Lundgren
Journal:  Lancet       Date:  2014-07-19       Impact factor: 79.321

8.  Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men.

Authors:  Vincent Lo Re; Giovanni Guaraldi; Mary B Leonard; Anthony R Localio; Jennifer Lin; Gabriella Orlando; Lucia Zirilli; Vincenzo Rochira; Jay R Kostman; Pablo Tebas
Journal:  AIDS       Date:  2009-10-23       Impact factor: 4.177

9.  Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals.

Authors:  Philip M Grant; Douglas Kitch; Grace A McComsey; Ann C Collier; Susan L Koletar; Kristine M Erlandson; Michael T Yin; Benedetta Bartali; Belinda Ha; Kathy Melbourne; Todd T Brown
Journal:  J Infect Dis       Date:  2016-06-20       Impact factor: 5.226

10.  Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.

Authors:  Jose I Bernardino; Amanda Mocroft; Patrick W Mallon; Cedrick Wallet; Jan Gerstoft; Charlotte Russell; Peter Reiss; Christine Katlama; Stephane De Wit; Laura Richert; Abdel Babiker; Antonio Buño; Antonella Castagna; Pierre-Marie Girard; Genevieve Chene; Francois Raffi; Jose R Arribas
Journal:  Lancet HIV       Date:  2015-09-30       Impact factor: 12.767

View more
  14 in total

Review 1.  Non-communicable Diseases in Pregnant and Postpartum Women Living with HIV: Implications for Health Throughout the Life Course.

Authors:  Risa M Hoffman; Caitlin Newhouse; Brian Chu; Jeffrey S A Stringer; Judith S Currier
Journal:  Curr HIV/AIDS Rep       Date:  2021-01-05       Impact factor: 5.071

2.  Evidence-informed practical recommendations for increasing physical activity among persons living with HIV.

Authors:  Jessica L Montoya; Catherine M Jankowski; Kelly K O'Brien; Allison R Webel; Krisann K Oursler; Brook L Henry; David J Moore; Kristine M Erlandson
Journal:  AIDS       Date:  2019-05-01       Impact factor: 4.177

3.  Current Considerations for Clinical Management and Care of People with HIV: Findings from the 11th Annual International HIV and Aging Workshop.

Authors:  Asante R Kamkwalala; Ankita Garg; Upal Roy; Avery Matthews; Jose Castillo-Mancilla; Jordan E Lake; Giada Sebastiani; Michael Yin; Todd T Brown; Angela R Kamer; Douglas A Jabs; Ronald J Ellis; Marta Boffito; Meredith Greene; Sarah Schmalzle; Eugenia Siegler; Kristine M Erlandson; David J Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2021-09-20       Impact factor: 2.205

Review 4.  Continued Interest and Controversy: Vitamin D in HIV.

Authors:  Evelyn Hsieh; Michael T Yin
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

5.  BONE QUALITY IN A YOUNG COHORT OF HIV-POSITIVE PATIENTS.

Authors:  A R Negru; C Tiliscan; A M Tudor; D I Munteanu; C Popescu; M Lazar; A Streinu-Cercel; V Arama; S S Arama
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Oct-Dec       Impact factor: 0.877

6.  Special Topics in the Care of Older People with HIV.

Authors:  Tessa Del Carmen; Carrie Johnston; Chelsie Burchett; Eugenia L Siegler
Journal:  Curr Treat Options Infect Dis       Date:  2019-11-08

7.  Adherence to Recommendations from Comprehensive Geriatric Assessment of Older Individuals with HIV.

Authors:  Christiana Bitas; Sian Jones; Harjot Kaur Singh; Mildred Ramirez; Eugenia Siegler; Marshall Glesby
Journal:  J Int Assoc Provid AIDS Care       Date:  2019 Jan-Dec

8.  Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.

Authors:  Gregory D Huhn; Joseph J Eron; Pierre-Marie Girard; Chloe Orkin; Jean-Michel Molina; Edwin DeJesus; Romana Petrovic; Donghan Luo; Erika Van Landuyt; Erkki Lathouwers; Richard E Nettles; Kimberley Brown; Eric Y Wong
Journal:  AIDS Res Ther       Date:  2019-08-29       Impact factor: 2.250

9.  Reduced bone mineral density among HIV infected patients on anti-retroviral therapy in Blantyre, Malawi: Prevalence and associated factors.

Authors:  Enock M Chisati; Demitri Constantinou; Fanuel Lampiao
Journal:  PLoS One       Date:  2020-01-14       Impact factor: 3.240

Review 10.  Influence of HIV Infection and Antiretroviral Therapy on Bone Homeostasis.

Authors:  María Victoria Delpino; Jorge Quarleri
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-02       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.